Treats Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism. ANDA 76521, held by Impax Laboratories. Carbidopa; Levodopa.
As of Nov 21, 2026, ANDA 76521 (Carbidopa and Levodopa), held by Impax Laboratories, was first approved by FDA on May 14, 2004, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Carbidopa and levodopa extended-release tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 14, 2004 | Original application | Approved | None posted |
| Carbidopa and Levodopa25MG;100MG · tablet, extended release;oral | Carbidopa; Levodopa | Rx |
| Carbidopa and Levodopa50MG;200MG · tablet, extended release;oral | Carbidopa; Levodopa | Rx |
| May 28, 2026 | Supplement 15Labeling · Standard review | Approved | None posted |
| Nov 21, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 6, 2010 | Supplement 4Labeling | Approved | None posted |
| May 14, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters